John Chrisinger

Medicine & Life Sciences

1. Neoplasms 100%
2. Sarcoma 80%
3. Hemangiosarcoma 71%
4. Liposarcoma 48%
5. Gene Fusion 45%
6. Survival 42%
7. Granular Cell Tumor 40%
8. Radiotherapy 31%
9. Lipoma 28%
10. ADI PEG20 27%
11. Whole Exome Sequencing 25%
12. Phosphoglycerate Dehydrogenase 25%
13. Neurofibrosarcoma 24%
14. Adamantinoma 24%
15. peroxisome-proliferator-activated receptor-gamma coactivator-1 24%
16. Retroperitoneal liposarcoma 23%
17. Mutation 22%
18. Desmoplastic Small Round Cell Tumor 22%
19. Perivascular Epithelioid Cell Neoplasms 22%
20. Osteoblastoma 22%
21. Neoplasm Metastasis 21%
22. Trophoblastic Neoplasms 21%
23. Fasciitis 20%
24. Chondrosarcoma 20%
25. Synovial Sarcoma 19%
26. Keratins 18%
27. Sclerosing Cholangitis 18%
28. Epithelioid Cells 18%
29. Monophenol Monooxygenase 18%
30. Mechanistic Target of Rapamycin Complex 1 17%
31. Costs and Cost Analysis 17%
32. Ewing's Sarcoma 17%
33. Pseudoangiomatous stromal hyperplasia 17%
34. Osteosarcoma 17%
35. Rhabdomyosarcoma 16%
36. Hyperparathyroidism 16%
37. Skin 16%
38. Progression-Free Survival 16%
39. Femur 16%
40. Temporal Bone 16%
41. Fibroma 15%
42. Giant Cell Tumors 15%
43. TOR Serine-Threonine Kinases 15%
44. Recurrence 15%
45. Sclerosis 15%
46. Giant Cells 15%
47. Chemoradiotherapy 15%
48. Microsatellite Repeats 15%
49. Bone and Bones 14%
50. Colitis 14%